Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death.

Depletion of T lymphocytes from allogeneic bone marrow transplants successfully prevents the development of graft-versus-host disease (GvHD) but is associated with impaired engraftment, immunosuppression, and abrogation of the graft-versus-leukemia effect. We therefore explored the possibility of selectively eliminating alloreactive T cells by CD95/CD95L-mediated activation-induced cell death (AICD) in a major histocompatibility complex allogeneic murine model system. Activation of resting or preactivated T lymphocytes from C3H/HeJ (H-2(k)) mice was induced with irradiated BALB/cJ (H-2(d)) mouse-derived stimulators. Substantial decrease (> or = 80%) of proliferative and lytic responses by activated alloreactive T cells was subsequently achieved by incubating the mixed lymphocyte culture with an agonistic monoclonal antibody to CD95, and residual T cells recovered did not elicit alloreactivity upon challenge to H-2(d). Depletion of alloreactive T lymphocytes by AICD was specific because reactivity to an I-A(d)-restricted ovalbumin (OVA) peptide by OVA-specific CD4(+) T cells mixed into the allogeneic T-cell pool and subjected to induction of AICD in the absence of OVA peptide could be preserved. Adoptive transfer of donor-derived allogeneic T lymphocytes, depleted from alloreactive T cells by AICD in vitro, in the parent (C3H/He) to F(1) (C3H/He x BALB/c) GvHD model prevented lethal GvHD. The results presented suggest that alloreactive T cells can effectively be depleted from allogeneic T cells by induction of AICD to prevent GvHD and might introduce a new strategy for the separation of GvH-reactive T cells and T cells mediating antiviral and possibly graft-versus-leukemia effects.

[1]  M. V. D. van den Brink,et al.  Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. , 2001, Blood.

[2]  J. Melo,et al.  Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. , 2001, Blood.

[3]  P. Krammer,et al.  TCR-Mediated Up-Regulation of c-FLIPshort Correlates with Resistance Toward CD95-Mediated Apoptosis by Blocking Death-Inducing Signaling Complex Activity1 , 2000, The Journal of Immunology.

[4]  J. Goldman,et al.  Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. , 2000, Blood.

[5]  H. Stauss,et al.  Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease. , 1999, Blood.

[6]  W. M. Smit,et al.  Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. , 1999, Blood.

[7]  J. Gribben,et al.  Transplantation of anergic histoincompatible bone marrow allografts. , 1999, The New England journal of medicine.

[8]  V. Calcaterra,et al.  Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. , 1999, Blood.

[9]  H. Prentice,et al.  Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis , 1999, Bone Marrow Transplantation.

[10]  Y. Aizawa,et al.  Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation , 1999 .

[11]  R. Siegel,et al.  Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. , 1999, Annual review of immunology.

[12]  R. Noelle,et al.  CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. , 1998, The Journal of clinical investigation.

[13]  J. Crawford,et al.  Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. , 1998, The Journal of clinical investigation.

[14]  N. Young,et al.  T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect , 1998, Bone Marrow Transplantation.

[15]  S. Dowdy,et al.  TCR antigen-induced cell death occurs from a late G1 phase cell cycle check point. , 1998, Immunity.

[16]  G. Szot,et al.  Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. , 1997, Blood.

[17]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[18]  D. Green,et al.  Unequal Death in T Helper Cell (Th)1 and Th2 Effectors: Th1, but not Th2, Effectors Undergo Rapid Fas/FasL-mediated Apoptosis , 1997, The Journal of experimental medicine.

[19]  D. Klatzmann,et al.  Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. , 1997, Blood.

[20]  N. Hensel,et al.  Preferential usage of T cell receptor (TCR) V β by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease , 1997, Bone Marrow Transplantation.

[21]  E. Podack,et al.  Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Elkon,et al.  A major role for the Fas pathway in acute graft-versus-host disease. , 1996, Journal of immunology.

[23]  K. Parker,et al.  Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. , 1996, Blood.

[24]  J. Ferrara,et al.  The Immunopathophysiology of Acute Graft‐Versus‐Host‐Disease , 1996, Stem cells.

[25]  A. Abbas,et al.  The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. , 1996, Immunity.

[26]  J. Ferrara,et al.  Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. , 1995, Journal of immunology.

[27]  Seamus J. Martin,et al.  Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas , 1995, Nature.

[28]  P. Krammer,et al.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) , 1995, Nature.

[29]  M. Eckhaus,et al.  Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. , 1994, Blood.

[30]  A. Barrett,et al.  Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. , 1994, Bone marrow transplantation.

[31]  S. Riddell,et al.  Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. , 1994, Blood.

[32]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[33]  P. Martin,et al.  Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans , 1993, The Journal of experimental medicine.

[34]  P. Krammer,et al.  Activation interferes with the APO-1 pathway in mature human T cells. , 1993, International immunology.

[35]  H. Heimpel,et al.  Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. , 1992, The New England journal of medicine.

[36]  M. Lenardo lnterleukin-2 programs mouse αβ T lymphocytes for apoptosis , 1991, Nature.

[37]  D. Loh,et al.  Receptor-stimulated death pathway is opened by antigen in mature T cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Lenardo Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. , 1991, Nature.

[39]  A. Heimberger,et al.  Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. , 1990, Science.

[40]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[41]  M. Zutter,et al.  Epstein-Barr virus lymphoproliferation after bone marrow transplantation. , 1988, Blood.

[42]  R. Hoffmann,et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .